Unusual presentation of cis-platinum neuropathy.
Symptoms and signs of cis-diamminedichloroplatinum II (DDP) neuropathy usually develop during treatment and stabilize or improve when DDP is stopped. We report three patients whose symptoms began 3 to 8 weeks after the last dose of DDP and progressed over 1 or 2 months to moderate-marked disability. The clinical picture in each was consistent with DDP neuropathy, and no other cause could be identified. Two of the patients improved over 8 and 27 months to become asymptomatic; the other died 2 months after presentation. It is important to recognize that DDP neuropathy can present after treatment has been discontinued since the clinical picture mimics the paraneoplastic dorsal root ganglionitis, which has a different prognosis.
Mollman
J E
JE
Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia.
Hogan
W M
WM
Glover
D J
DJ
McCluskey
L F
LF
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005528:Foot; D006225:Hand; D006801:Humans; D007866:Leg; D008875:Middle Aged; D009422:Nervous System Diseases / Q000139:chemically induced*; D012677:Sensation / Q000187:drug effects; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000556:secondary
D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin